We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Circassia Group Plc | LSE:CIR | London | Ordinary Share | GB00BJVD3B28 | ORD 0.08P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 34.00 | 33.10 | 34.90 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Jan 2022 to Jan 2025
TIDMCIR
RNS Number : 6307Q
Circassia Group Plc
29 June 2022
Circassia Group PLC
("Circassia" or the "Company")
Update regarding Beyond Air product approval
Oxford, UK - 29 June 2022: Circassia Group PLC (AIM: CIR), a company engaged in the design, development and commercialisation of medical devices for the diagnosis and management of asthma, notes the announcement yesterday from BeyondAir, Inc. (NASDAQ: XAIR) ("BeyondAir"), confirming that it had received approval from the U.S. Food and Drug Administration (FDA) for its LungFit(R) PH device ("Approval") for the treatment of hypoxic respiratory failure in neonates using nitric oxide generated from ambient air.
As a result of this news and in accordance with the terms of a previously announced settlement agreement(1) between Circassia and BeyondAir, the Company is entitled to receive payments of $10.5 million in total, in three instalments as follows:
-- $2.5m within 60 days of Approval; plus -- $3.5m within 60 days of the first anniversary of Approval; plus -- $4.5m within 60 days of the second anniversary of Approval.
In addition, Circassia is entitled to a royalty of 5% of net sales of the device, commencing on the second anniversary of Approval, up to a maximum of $6m.
(1) RNS Number 8038Z (26 May 2021)
For further information, please contact: Circassia Group plc Ian Johnson, Executive Chairman Michael Roller, Chief Financial Officer +44 (0) 1865 405560 Singer Capital Markets (Nominated Adviser & Broker) +44 (0) 20 7496 Aubrey Powell / Jen Boorer 3000
About Circassia
Our ambition is to improve the quality of life of millions of people suffering from asthma. The company is engaged in the design, development and commercialisation of medical devices for the diagnosis and management of asthma. Today our device, NIOX VERO, is used by healthcare professionals and leading research organisations. We passionately believe in empowering everyone to manage their health at home and are developing NIOX for home use to meet this need. At present, Circassia provides products and services in around 50 countries. For more
information please visit www.circassia.com .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCSEISUUEESEIM
(END) Dow Jones Newswires
June 29, 2022 06:00 ET (10:00 GMT)
1 Year Circassia Chart |
1 Month Circassia Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
